Mount Sinai Researcher Launches Three Studies of Alzheimer’s Disease in Asian Americans
Clara Li, PhD, a clinical neuropsychologist and Associate Professor, Psychiatry, at the Icahn School of Medicine at Mount Sinai, has received new grants that will total more than $12 million from the National Institute on Aging (NIA), part of the National Institutes...
Mount Sinai Receives Five-Year Grant to Support First-of-Its-Kind Translational Science Program for Nurses
Mount Sinai’s Center for Nursing Research and Innovation (CNRI) is developing a first-of-its-kind program that supports Doctor of Nursing Practice (DNP) students from underrepresented minority communities and disadvantaged backgrounds to become experts in translating...
Mount Sinai Researchers Publish First Genome-Wide Analysis of Binge Eating Disorder
Binge eating disorder is the most common eating disorder in the United States, thought to affect as many as 3 percent of people during their lifetimes. Yet it remains poorly understood. Now, researchers from the Icahn School of Medicine at Mount Sinai have made...
Could Personalized PSA Levels Enhance Prostate Cancer Screening?
Prostate-specific antigen (PSA) screening has long been the gold standard for detecting prostate cancer at an early stage, aiming to improve treatment outcomes and increase survival rates. But the screening tool is not without its controversies. PSA levels can be...
Here’s What to Know About the First Approved Pill Treatment for Postpartum Depression
On Friday, August 4, 2023, the U.S. Food and Drug Administration (FDA) approved Zurzuvae™ (zuranolone), developed by pharmaceutical firms Biogen and Sage Therapeutics, to treat postpartum depression. The treatment is a pill taken once daily for 14 days, and is the...
AI Spotlight: Mapping Out Links Between Drugs and Birth Defects
Birth defects can be linked to many factors—genetic, environmental, even pure chance. Characterizing the links of any factor to congenital abnormalities is a daunting task, given the vastness of the problem. In the face of this challenge, a team of researchers at the...
Mount Sinai’s Role in Hemodialysis: From the First Treatment in the United States to Continuing Innovations
It has been more than 75 years since Mount Sinai conducted the first hemodialysis treatment in the United States in 1948, a monumental accomplishment, and Mount Sinai continues to play a leading role in research to help patients in need of this lifesaving treatment....
Mount Sinai Researchers Play a Prominent Role in a Wide Probe Into Long COVID
RECOVER—Researching COVID to Enhance Recovery—is a nationwide initiative dedicated to understanding why some people develop long-term symptoms following COVID-19 infection. Recently, for the first time, the project yielded outcomes that are expected to help...
AI Spotlight: Guiding Heart Disease Diagnosis Through Transformer Models
Electrocardiograms (ECGs) are often used by health providers to diagnose heart disease. At times, irregularities in the recordings are too subtle to be detected by human eyes but can be identified by artificial intelligence (AI). Mount Sinai researchers have developed an AI model, called HeartBEiT, for ECG analysis, which works by interpreting ECGs as language.
